Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2026-01-07 @ 10:46 AM
Study NCT ID:
NCT05921760
Status:
COMPLETED
Last Update Posted:
2025-07-15
First Post:
2023-04-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Sponsor:
Servier Bio-Innovation LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-23
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-21
Completion Date Type:
ACTUAL
First Submit Date:
2023-04-21
First Submit QC Date:
None
Study First Post Date:
2023-06-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-14
Last Update Post Date:
2025-07-15
Last Update Post Date Type:
ACTUAL